Compare BlackRock TCP Capital Corp (TCPC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BlackRock TCP Capital Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? BlackRock TCP Capital Corp trades at $4.04 (market cap $337.71M), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 377.7× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 18.88% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold BlackRock TCP Capital Corp for 88 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TCPC | VRTX | |
|---|---|---|
Market Cap | $337.71M | $127.55B |
Volume | 436,109 | 1,487,944 |
Sector | Financials | Health |
52-Week High | $6.20 | $557.96 |
52-Week Low | $3.13 | $407.37 |
Typical Hold Time | 88 Days | 120 Days |
Enterprise Value | $1.09B | $121.68B |
Dividend Yield | 18.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TCPC trades at $3.94, down 1.25% today, with a bearish technical signal and mixed fundamentals. The company reported negative revenue and net income for 2025, though recent earnings beat expectations. A strategic portfolio sale of $523 million aims to reduce leverage, while analyst sentiment leans cautious with 69% hold ratings. The stock shows a low P/B ratio of 0.61, suggesting potential undervaluation relative to assets.
Outlook remains challenged by persistent negative profitability and revenue trends, with projected declines through 2026. The strategic review and dividend yield near 4.3% offer some upside, but risks include class action lawsuits and execution uncertainty. Investors should weigh the discount to book value against fundamental headwinds.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
